The effectiveness of the use of ethylmethylhydroxypyridine of succinate in patients with cerebrovascular pathology against the background of diabetes and metabolic syndrome

Authors:
E.V. EKUSHEVA^1,2, E.V. BIRYUKOVA³

¹Federal State Budgetary Institution "Academy of Postgraduate Education "Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency", Moscow, Russia;
²Belgorod State National Research University, Belgorod, Russia;
³A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2020, Vol. 120, No. 12

Abstract:
Arterial hypertension, diabetes mellitus, obesity, and dyslipidemia remain the main risk factors for circulatory diseases and the leading causes of death worldwide. The combination of these conditions significantly increases the likelihood of developing and more rapidly progressing cardiovascular and cerebrovascular pathologies. Improving approaches to the diagnosis and treatment of these conditions is a priority issue in modern medicine. Currently, there is no universal drug that can address all aspects of the pathological process in both cerebrovascular diseases and diabetes mellitus, and the issue of rational use of medications in patients with comorbid pathology has not been fully resolved. The complex clinical challenge lies not only in timely detection and correct diagnosis but also in selecting the safest and most effective drug. Several clinical studies have demonstrated the efficacy of Mexidol in treating this category of patients, determined by its complex, pleiotropic, and multimodal mechanism of action. Key words: cerebrovascular diseases, diabetes mellitus, metabolic syndrome, antioxidants, Mexidol.